Blood Adv
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
Related Questions
Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...
New comment by at John Theurer Cancer Center Hackensack Univ Med Center ( July 26, 2022)
What conditioning do you use?